Australia markets open in 8 hours 43 minutes

    +2.20 (+0.03%)

    +0.0026 (+0.33%)
  • ASX 200

    +2.10 (+0.03%)
  • OIL

    +0.03 (+0.05%)
  • GOLD

    -5.30 (-0.30%)

    -257.79 (-0.36%)
  • CMC Crypto 200

    -53.58 (-4.12%)

Breast Cancer Therapeutics Market to Exhibit 13.1% CAGR and Hit USD 55.27 Billion by 2027; Increasing Patient Population to Aid Growth in Latin America: Fortune Business Insights™

Fortune Business Insights
·6-min read

Breast Cancer Therapeutics Market Key Players Studied in this Report are Genentech (F. Hoffmann-La Roche Ltd) (South San Francisco, U.S.), Eli Lilly and Company (Indianapolis, U.S.), Novartis AG (Basel, Switzerland), AstraZeneca (Cambridge, U.K.), Pfizer Inc. (New York City, U.S.),n Sanofi (Paris, France), Eisai Co. Ltd. (Tokyo, Japan), Kyowa Kirin (Tokyo, Japan), Bristol Myers Squibb (Celgene Corporation) (New York City, U.S.), Merck & Co., Inc. (Kenilworth, U.S.)

Pune, India, March 02, 2021 (GLOBE NEWSWIRE) -- According to the report, Breast Cancer Therapeutics market size is projected to reach USD 55.27 Billion by 2027. Breast Cancer Therapeutics Market was worth USD 21.58 billion in 2019 and will exhibit a CAGR of 13.1% during the forecast period. The global breast cancer therapeutics market is set to gain impetus from the ongoing research and developments to come up with state-of-the-art drugs.

Nowadays, several renowned companies are constantly launching new breast cancer therapeutics worldwide. Most of these drugs are meant for the treatment of those types of breast cancers that were previously untreatable or the available drugs were not successful for providing positive outcomes. These factors are expected to accelerate the breast cancer therapeutics market growth in the forthcoming years. However, certain severe reactions can come up while undergoing this type of cancer therapeutics, such as targeted therapies. Patients can suffer from nausea, fatigues, rashes, gastrointestinal problems, or high blood pressure. These may hinder growth.

Request a Sample Copy of the Research Report:

COVID-19 Pandemic to Affect Growth Moderately as Cancer Requires Immediate Attention

Based on therapy, the hormonal therapy segment generated 8.3% in terms of the breast cancer therapeutics market share in 2019. It is likely to exhibit lower growth in the coming years on account of the rising availability of their generic equivalents.

Regionally, North America procured USD 10.34 billion in 2019 in terms of revenue. The rising prevalence of breast cancer, presence of numerous providers of breast cancer therapeutics, and the surging awareness of this condition are expected to augment growth in this region. The American Cancer Society, for instance, declared that the U.S. is set to experience around 276,480 new cases of invasive breast cancer in 2020.

Europe, on the other hand, is likely to retain its second position fueled by the high demand for advanced and sophisticated breast cancer therapeutics. In Asia Pacific, the market would grow rapidly because of the increasing healthcare expenditure. Lastly, the Middle East & Africa and Latin America are anticipated to show robust growth on account of the rising patient population in both regions.

Click here to get the short-term and long-term impacts of COVID-19 on this Market.

Please visit:

Increasing Development of State-of-the-art Products to Favor Growth

This global market houses a large number of companies that are nowadays striving to gain fast track approvals from government healthcare agencies to distribute and market their products. Some of the others are focusing on developing unique breast cancer therapeutics to cater to the unmet demand. Below are the two latest industry developments:

September 2020: Lupin introduced Lapatinib Tablets, 250 mg, after its partner Natco Pharma received approval from the USFDA. These will be used to treat patients suffering from metastatic or advanced breast cancer.

November 2019: Daiichi Sankyo Company and AstraZeneca declared that their HER2-directed antibody-drug conjugate named Enhertu was approved by the USFDA. It is meant for the treatment of adult patients living with metastatic or unresectable HER2-positive breast cancer.

Quick Buy - Breast Cancer Therapeutics Market Research Report:

  • Genentech (F. Hoffmann-La Roche Ltd) (South San Francisco, U.S.)

  • Eli Lilly and Company (Indianapolis, U.S.)

  • Novartis AG (Basel, Switzerland)

  • AstraZeneca (Cambridge, U.K.)

  • Pfizer Inc. (New York City, U.S.)

  • Sanofi (Paris, France)

  • Eisai Co. Ltd. (Tokyo, Japan)

  • Kyowa Kirin (Tokyo, Japan)

  • Bristol Myers Squibb (Celgene Corporation) (New York City, U.S.)

  • Merck & Co., Inc. (Kenilworth, U.S.)

Have Any Query? Ask Our Experts:

Global Breast Cancer Therapeutics Market Segmentation:

By Application:

  • General Surgery

  • Gynecology

  • Urology

  • Orthopedics

By Geography:

  • North America (USA, Canada)

  • Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

  • Latin America (Brazil, Mexico, Rest of Latin America)

  • Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)

Get your Customized Research Report:

Have a Look at Related Reports:

Neonatal Intensive Care Market Size, Share & Industry Analysis, By Product (Neonatal Incubators, Neonatal Phototherapy Equipment, Neonatal Ventilators, Neonatal Monitors, and Others), By End User (Hospitals, and Specialty Clinics), and Regional Forecast, 2020-2027

Lymphoma Treatment Market Size, Share & Industry Analysis, By Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, and Others), By Disease Type (Non-Hodgkin Lymphoma, and Hodgkin Lymphoma), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Regional Forecast, 2019-2026

Diabetic Neuropathy Market Size, Share & Industry Analysis, By Disease Type (Peripheral, Autonomic, Proximal, and Focal), By Drug Class (Anti-Depressants, Anti-Seizures, Opioid, Non-Steroidal Anti-Inflammatory, and others), By Distribution Channel (Hospital Pharmacies, Retails Pharmacies & Stores, and Online Pharmacies), and Regional Forecast, 2019-2026

Teleradiology Market Size, Share & Industry Analysis, By Imaging Technique (X-Ray, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Ultrasound, Nuclear Medicine, and Others), By Component (Services & Software, and Product), By End User (Hospitals & Clinics, Diagnostic Centers and Others), and Regional Forecast, 2019-2026

Transcatheter Heart Valve Replacement (THVR) Market Size, Share & Industry Analysis, By Product Type (Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral Valve Replacement (TMVR), and Transcatheter Pulmonary Valve Replacement (TPVR)), By End User (Hospitals, and Specialty Clinics& Others), and Regional Forecast, 2019-2026

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Fortune Business Insights™
LinkedIn | Twitter | Blogs